Accidental administration of the remifentanil formulation Ultiva™ into the epidural space and the complete time course of its consequences: a case report
Abstract Background Ultiva™ contains the potent short-acting μ-opioid receptor agonist remifentanil hydrochloride, and it is commonly administered intravenously during general anesthesia. It is not approved for epidural or intrathecal use in clinical practice because it contains glycine as an acidic...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2016-08-01
|
| Series: | JA Clinical Reports |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40981-016-0046-5 |